Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 12/20 | 1.00 |
| ▸ | MMP8 | P22894 | 4/20 | 1.00 |
| ▸ | MMP1 | P03956 | 7/20 | 0.66 |
| ▸ | MMP3 | P08254 | 2/20 | 0.66 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.61 |
| ▸ | MMP2 | P08253 | 1/20 | 0.61 |
| ▸ | MMP9 | P14780 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7208360 | 0.95 | MMP13 (0.90) | MMP13MMP8MMP1MMP3ADAM17 | |
| SCHEMBL7212113 | 0.89 | MMP13 (0.80) | MMP13MMP8MMP1MMP3ADAM17 | |
| SCHEMBL20054093 | 0.84 | MMP13 (0.72) | MMP13MMP8MMP1MMP9HTT | |
| SCHEMBL14379753 | 0.82 | MMP13 (0.70) | MMP13MMP8MMP1ADAM17MMP9 | |
| SCHEMBL10570690 | 0.82 | MMP13 (0.70) | MMP13MMP8MMP1ADAM17MMP2 | |
| SCHEMBL7082733 | 0.82 | MMP13 (0.70) | MMP13MMP8MMP1MMP2MMP9 | |
| SCHEMBL29130800 | 0.82 | MMP13 (0.70) | MMP13MMP8MMP1MMP3HTT | |
| SCHEMBL7207812 | 0.81 | MMP13 (0.69) | MMP13MMP8MMP1MMP3ADAM17 | |
| SCHEMBL24175875 | 0.81 | MMP13 (0.68) | MMP13MMP8MMP1MMP3ADAM17 | |
| SCHEMBL24175871 | 0.81 | MMP13 (0.68) | MMP13MMP8MMP1MMP3ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030130271-A1 | 1,3-Diheterocyclic metalloprotease inhibitors | THE PROCTER & GAMBLE COMPANY | 2003-07-10 | — | — | US | disclosed |
| EP-0939628-B1 | THIOL SULFONE METALLOPROTEASE INHIBITORS | MONSANTO CO (US) | 2003-03-05 | — | — | EP | disclosed |
| EP-0927168-B1 | 1,3-DIHETEROCYCLIC METALLOPROTEASE INHIBITORS | PROCTER & GAMBLE (US) | 2002-11-06 | — | — | EP | disclosed |
| US-6469000-B1 | TREATING ARTHRITIS, CANCER, CARDIOVASCULAR DISORDERS, SKIN DISORDERS, OCULAR DISORDERS, INFLAMMATION AND GUM DISEASE | THE PROCTER & GAMBLE CO. | 2002-10-22 | — | — | US | disclosed |
| US-6465474-B1 | TREATMENT OF SUCH AS OSTEOARTHITIS, RHEUMATOID ARTHRITIS, PREVENTION OR ARREST OF TUMOR GROWTH AND METASTASIS, CORNEAL ULCERATION, LACK OF CORNEAL HEALING, MACULAR DEGENERATION, PERIODONTAL DISEASE, GINGIVITIS | THE PROCTER & GAMBLE COMPANY | 2002-10-15 | — | — | US | disclosed |
| US-6150370-A | 1,3-DINITROCYCLIC COMPOUND TREATS NUMEROUS DISEASES CAUSED BY UNDESIRED METALLOPROTEASE ACTIVITY, SUCH AS TUMOR METASTASIS, OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, SKIN INFLAMMATION, ULCERATIONS, AND PERIODONTITIS | THE PROCTER & GAMBLE COMPANY (US) | 2000-11-21 | — | — | US | disclosed |
| US-6013649-A | BOND DISORDERS; AUTOIMMUNE DISEASES; ANTITUMOR AGENTS | MONSANTO COMPANY (US) | 2000-01-11 | — | — | US | disclosed |
| EP-0939628-A4 | THIOL SULFONE METALLOPROTEASE INHIBITORS | MONSANTO CO (US) | 1999-12-22 | — | — | EP | disclosed |
| EP-0939628-A1 | THIOL SULFONE METALLOPROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1999-09-08 | — | — | EP | disclosed |
| EP-0927168-A1 | 1,3-DIHETEROCYCLIC METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 1999-07-07 | — | — | EP | disclosed |
| WO-1998008822-A1 | 1,3-DIHETEROCYCLIC METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 1998-03-05 | — | — | WO | disclosed |
| WO-1998003164-A1 | THIOL SULFONE METALLOPROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1998-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130271-A1 | 1,3-Diheterocyclic metalloprotease inhibitors | ADAM17, TIMP3, MMP3 | MMP13 15/4885MMP8 50/4885MMP1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.